• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to medicinal preparations which can be administered orally and contain a fixed combination of at least one locally acting analgesic with a rapid onset of action and at least one systemically acting analgesic with a sustained action.
    公开号:US20010002999A1
    申请号:US09/402,737
    申请日:1998-04-02
    公开日:2001-06-07
    发明作者:Dieter Neuser；Monika Fierus；Wolfgang Wiehl
    申请人:Bayer AG；
    IPC主号:A61K31-19
    专利说明:
    [0001] The present invention relates to medicinal preparations which can be administered orally and contain a fixed combination of at least one locally acting analgesic with a rapid onset of action and at least one systemically acting analgesic with a sustained action. [0001]
    [0002] Locally acting analgesics with a rapid onset of action which can be used, for example, in the form of sprays or pastilles are already known. Local anaesthetics of this type display their action after less than one minute but have only a short duration of action so that frequent remedication is necessary, which adversely affects safety and patient compliance. [0002]
    [0003] Examples of particularly interesting locally acting analgesics which may be mentioned are the benzocaines. They inhibit impulse formation and conduction in nerves by blocking the flow of sodium. [0003]
    [0004] Systemically acting analgesics, such as, for example, NSAIDs, in particular acetylsalicylic acid (ASA), represent another useful possibility for alleviating pain. These analgesics reduce the sensitivity of the nociceptors, and the alleviation of pain can be explained by the inhibition of prostaglandin synthesis. With most of these systemically acting analgesics, the maximum activity is not reached until after about 1-2 hours. [0004]
    [0005] An object of the present invention is to satisfy the need, which has existed for a long time, to provide a preparation which can be administered orally and which combines, in a simple and reliable manner, an immediate analgesic action with a sustained action. [0005]
    [0006] The active substances which can be used as locally acting analgesics (element A) are those which show a significant onset of action within a period of up to 10 minutes, preferably of 4 minutes, in particular of 1 minute and very particularly of 30 seconds. [0006]
    [0007] The locally acting analgesics (combination element A) are expediently employed in amounts of from 0.5 to 100 mg, preferably 1 to 60 mg and, in particular, 2 to 30 mg, per individual administration form. [0007]
    [0008] The combination according to the invention may contain one or more local anaesthetics as element A, for example 1, 2 or 3. Combinations with only one compound of element A are of particular interest. [0008]
    [0009] The active substances of element A are substantially known. Particularly suitable examples which may be mentioned are ester-type local anaesthetics such as benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacaine, tricaine etc. Mention may likewise be made of anilide-type local anaesthetics such as lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine, vadocaine, etc. [0009]
    [0010] It is also possible to employ other local anaesthetics such as, for example, pramoxine or essential oils such as menthol or eucalyptus oil. [0010]
    [0011] The systemically acting analgesics which can be employed as element B are likewise substantially known. Mention may preferably be made of non-steroidal antiinflammatory drugs (NSAIDs) such as, for example, phenylacetic acid derivatives such as aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac etc., arylacetic acid derivatives such as acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, etc., para-aminophenol derivatives such as acetanilide, etc., propionic acid derivatives such as alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, salicylic acid derivatives such as acetylsalicylic acid (ASA), aluminium ASA and other salts, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, etc., pyrazolone derivatives such as amidopyrine, dipyrone etc., oxycam derivatives such as droxicam, isoxicam, piroxicam etc., phenylbutazone derivatives such as azapropazone, bumadizone calcium, oxyphenbutazone etc., pyranoindoleacetic acid derivatives such as etodolac etc., anthranilic acid derivatives such as glafenine, Na meclofenamate, mefenamic acid, morniflumate etc., indole derivatives such as indomethacin etc., paracetarnol and paracetamol derivatives and other NSAIDs such as anirolac, benzpiperylone, benzydamine hydrochloride, Na butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuproxam, indoprofen, isamfazone, meloxicam, metiazinic acid, metifenazone, nifenazone, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid, ramifenazone etc. [0011]
    [0012] The systemically acting analgesics of element B are employed according to the invention in amounts of from 5 to 1500 mg, preferably 8 to 1000 mg, in particular 10 to 800 mg, per dosage form. [0012]
    [0013] The local analgesics preferably employed as element A are rapidly acting and have an optimal duration of action lasting 0.5 to 120 minutes, preferably 2 to 60 minutes, in particular 5 to 30 minutes. The systemic analgesics preferably used as element B are those where a significant action has its onset after 15 minutes and lasts for up to 24 hours, preferably those whose action has its onset after 20 minutes and lasts for up to 12 hours, in particular up to 8 hours. [0013]
    [0014] Particularly interesting combinations according to the invention are those which contain as element A an ester-type local anaesthetic, in particular benzocaine, and contain as element B propionic acid derivatives or salicylic acid derivatives, in particular ASA. [0014]
    [0015] Preferred systemic analgesics are those which have a duration of action of at least 3 hours. [0015]
    [0016] The combination according to the invention is particularly suitable for treating inflammatory and/or painful disorders of the oropharynx, in particular for treating pharyngitis, laryngitis, tonsillitis, stomatitis, gingivitis of a variety of aetiologies. The combination product according to the invention is expediently administered orally. [0016]
    [0017] The combination can be employed in conventional formulations, the intention being that the local anaesthetic is released first, and it being possible for the systemically acting analgesic where appropriate also to be present in depot form. The following may be mentioned as examples of such preparations: press-coated tablets, coated pastilles, chewing gum, hard caramel with liquid, semisolid or solid core. They are produced by conventional methods using customary ancillary substances. [0017] EXAMPLES Example 1
    [0018] A tablet of the following composition may be mentioned by way of example: [0018]
    [0019] ASA core tablet: [0019]
    [0020] 500 mg of ASA are compressed with 30 mg of ascorbic acid, 75 mg of sucrose, 47 mg of microcrystalline cellulose, 2 mg of saccharin (550 x) and 6 ml of orange juice flavouring to give a tablet with a total weight of 660 mg. These core tablets are coated uniformly with a benzocaine-containing coating syrup, applying a total of about 5 mg of benzocaine and 602 mg of coating syrup. The aforementioned tablet shows a marked analgesic action only two minutes after intake, and this is sustained for a period of more than 3 hours. [0020] Example 2
    [0021] A core tablet containing 300 mg of naproxen is coated with a coating syrup which contains 500 mg of lidocaine in analogy to Example 1. This combination preparation shows an onset of action after 2 minutes and a duration of action of more than 6 hours. [0021]
    权利要求:
    Claims (4)
    [1" id="US-20010002999-A1-CLM-00001] 1. Preparation which can be administered orally and contains a fixed combination of at least one locally acting analgesic with a rapid onset of action (element A) with at least one systemically acting analgesic with a sustained action (element B).
    [2" id="US-20010002999-A1-CLM-00002] 2. Preparation according to
    claim 1 , characterized in that the active substance employed as element A shows an optimal duration of action of from 0.5 to 120 minutes, and the active substance employed as element B has an action of from 15 minutes up to 24 hours.
    [3" id="US-20010002999-A1-CLM-00003] 3. Preparation according to
    claim 1 , characterized in that elements A and B are selected so that the fixed combination has a duration of action of from 2 minutes up to 12 hours.
    [4" id="US-20010002999-A1-CLM-00004] 4. Process for producing a preparation according to
    claim 1 , characterized in that the fixed combination of an active substance of element A and an active substance of element B are converted together with conventional ancillary substances and carriers and, where appropriate, other compatible active substances into a suitable administration form.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6929805B2|2005-08-16|Analgesic combination
    US6166083A|2000-12-26|Suckable flurbiprofen lozenges for treatment of sore throat
    US5196436A|1993-03-23|Dextromethorphan antitussive compositions
    CA2451842C|2008-09-09|Chewable product including active ingredient
    EP0137668B1|1990-01-17|Ibuprofen, flurbiprofen and their therapeutic use
    RU2203046C2|2003-04-27|Method for flubiprophen tablet making
    PL187242B1|2004-06-30|Buccal delivery system
    ES2373957T3|2012-02-10|COMBINATION OF FLUPIRTINA AND TRAMADOL.
    Pfaffenrath et al.1995|Analgesics and NSAIDs in the treatment of the acute migraine attack
    RU2005115883A|2006-01-27|CONTROLLED RELEASE COMPOSITIONS
    WO1998052545A1|1998-11-26|Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
    BRPI0614091A2|2011-03-09|solid extended release pharmaceutical composition containing carbidopa and levodopa
    CA2570474A1|2006-01-12|A combination composition comprising paracetamol and ibuprofen
    HU0401582A2|2004-11-29|Pharmaceutical compositions containing combination of nsaid and pde-4 inhibitors and their use
    CA2279184C|2009-04-21|Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
    WO2010120253A1|2010-10-21|Thiocolchicoside and non-steroidal anti-inflammatory drug combinations
    CN1230176C|2005-12-07|Use of 4-|-6-methyl-2-| thieno[2,3-D] pyrimidine for treatment of pain
    MXPA99009225A|2000-06-05|Analgesic combination
    DE4319438C1|1994-06-01|Analgesic and/or antiinflammatory medicaments - contg. sepd enantiomers of ketoprofen
    WO2019098983A1|2019-05-23|Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation
    HUT64216A|1993-12-28|Process for producing cough diminishing medical preparative containing dextrometorphane
    GB2189142A|1987-10-21|Relief of tonsillectomy pain
    AU2003203346A1|2004-10-21|Non-steroidal anti inflammatory drug and glucosamine combination
    MXPA99010548A|2000-09-04|Process for making flurbiprofen lozenges
    同族专利:
    公开号 | 公开日
    PL190863B1|2006-02-28|
    HU225601B1|2007-05-02|
    HU0003636A2|2001-05-28|
    DK0979087T3|2004-03-08|
    YU52999A|2002-06-19|
    US6929805B2|2005-08-16|
    WO1998046235A1|1998-10-22|
    RU2218180C2|2003-12-10|
    BR9808875A|2000-07-11|
    ES2210754T3|2004-07-01|
    CN1252725A|2000-05-10|
    PT979087E|2004-03-31|
    KR20010006348A|2001-01-26|
    NZ500262A|2002-04-26|
    DE19715594A1|1998-10-22|
    AR012417A1|2000-10-18|
    EP0979087B1|2003-11-12|
    CN1177589C|2004-12-01|
    TR199902396T2|2000-01-21|
    CA2285979A1|1998-10-22|
    NO323022B1|2006-12-27|
    HU0003636A3|2001-12-28|
    JP2002503221A|2002-01-29|
    AT253919T|2003-11-15|
    PL336154A1|2000-06-05|
    EP0979087A1|2000-02-16|
    CA2285979C|2009-11-24|
    RS49620B|2007-08-03|
    NO994663D0|1999-09-24|
    DE59810166D1|2003-12-18|
    AU742622B2|2002-01-10|
    KR100532647B1|2005-12-02|
    AU7428698A|1998-11-11|
    NO994663L|1999-09-24|
    HK1027505A1|2001-01-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5609884A|1992-08-31|1997-03-11|G. D. Searle & Co.|Controlled release naproxen sodium plus naproxen combination tablet|US20030035839A1|2001-05-15|2003-02-20|Peirce Management, Llc|Pharmaceutical composition for both intraoral and oral administration|
    US6863901B2|2001-11-30|2005-03-08|Collegium Pharmaceutical, Inc.|Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration|
    US20050069580A1|2001-12-05|2005-03-31|Collegium Pharmaceutical, Inc.|Compositions containing both sedative and non-sedative antihistamines and sleep aids|
    EP1550441A1|2004-01-05|2005-07-06|Bionics Pharma Gmbh|Compositions for a synergic topical therapy of neuromuscular pain|
    US20080207593A1|2007-02-28|2008-08-28|Collegium Pharmaceutical, Inc.|Antihistamine Combination|
    US20110152838A1|2008-08-01|2011-06-23|Tian Xia|Devices for Delivering a Medicament and Methods for Ameliorating Pain|
    US20120017893A1|2008-08-01|2012-01-26|Tian Xia|Methods for ameliorating pain and devices for delivering a medicament|
    US20130049931A1|2011-08-25|2013-02-28|Elwha LLC, a limited liability company of the State of Delaware|Systems, devices, methods, and admixtures of transponders and food products for indication of food attributes|
    US8690839B2|2008-08-01|2014-04-08|Tian Xia|Devices for delivering a medicament and connector for same|
    US9248266B2|2013-12-17|2016-02-02|Biovision Technologies, Llc|Method of performing a sphenopalatine ganglion block procedure|
    US9516995B2|2013-12-17|2016-12-13|Biovision Technologies, Llc|Surgical device for performing a sphenopalatine ganglion block procedure|
    US9694163B2|2013-12-17|2017-07-04|Biovision Technologies, Llc|Surgical device for performing a sphenopalatine ganglion block procedure|
    US10016580B2|2013-12-17|2018-07-10|Biovision Technologies, Llc|Methods for treating sinus diseases|
    US20180195534A1|2015-09-04|2018-07-12|Knorr-Bremse Systeme Fuer Nutzfahrzeuge Gmbh|Pressure-Medium Unit, Having a Housing Produced by Injection Molding and Composed of Plastic, and Method for Producing Said Pressure-Medium Unit|
    US10525240B1|2018-06-28|2020-01-07|Sandler Scientific LLC|Sino-nasal rinse delivery device with agitation, flow-control and integrated medication management system|GB1026501A|1961-10-13|1966-04-20|Upjohn Co|Improvements in or relating to steroids and the manufacture thereof|
    US4446140A|1981-12-10|1984-05-01|Nelson Research & Development Company|Method and composition for treating mouth pain|
    DE3328401A1|1983-08-05|1985-02-21|Merckle GmbH, 7902 Blaubeuren|INJECTABLE SOLUTION FOR TREATING INFLAMMATION|
    US4851233A|1986-10-06|1989-07-25|Warner-Lambert Company|Sustained release formulations|
    US5064858A|1988-08-17|1991-11-12|Spectrum Pharmaceutical Corporation|Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease|
    DE69014513T2|1989-09-21|1995-05-24|American Cyanamid Co|"Once a day" pulsed minocycline delivery system.|
    IE66933B1|1990-01-15|1996-02-07|Elan Corp Plc|Controlled absorption naproxen formulation for once-daily administration|
    IT1242642B|1990-04-17|1994-05-16|Alfa Wassermann Spa|INJECTABLE FORMULATIONS CONTAINING NAPROXEN SODIUM SALT.|
    GB9121204D0|1991-10-04|1991-11-20|Euro Celtique Sa|Medicament|
    SG42869A1|1992-08-05|1997-10-17|Faulding F H & Co Ltd|Pelletised pharmaceutical composition|
    US5451409A|1993-11-22|1995-09-19|Rencher; William F.|Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends|
    US5702723A|1994-08-02|1997-12-30|Griffin; David|Multi-stage delivery system for ingestible medications or nutrients|
    TW483763B|1994-09-02|2002-04-21|Astra Ab|Pharmaceutical composition comprising of ramipril and dihydropyridine compound|
    US5547948A|1995-01-17|1996-08-20|American Home Products Corporation|Controlled release of steroids from sugar coatings|
    WO1996029986A1|1995-03-29|1996-10-03|The Procter & Gamble Company|Antitussive microcapsules|US6423697B1|1999-01-14|2002-07-23|Mark Friedman|Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm|
    AU1713501A|1999-11-23|2001-06-04|Robert Gordon University, The|Bilayered buccal tablets comprising nicotine|
    WO2001045678A2|1999-12-21|2001-06-28|Id Pharma Gmbh|Medicament, a method for its production and the use thereof|
    KR20010069756A|2001-05-08|2001-07-25|유형선|Method for controlled release of acemetacin in the intestinal tract and more particularly in the colon|
    DE102004040630A1|2004-08-21|2006-03-09|Balaban, Romulus, Dr.med.|Combination therapy with procaine|
    DE102008007212B3|2008-02-01|2009-10-15|BSH Bosch und Siemens Hausgeräte GmbH|Housing for driving an electrical device, in particular a household appliance|
    WO2019064090A1|2017-09-28|2019-04-04|Zenvision Pharma Llp|Novel pharmaceutical composition comprising mefenamic acid and other analgesic|
    法律状态:
    1999-10-08| AS| Assignment|Owner name: BAYER AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEUSER, DIETER;FIERUS, MONIKA;WIEHL, WOLFGANG;REEL/FRAME:010409/0084;SIGNING DATES FROM 19990823 TO 19990825 Owner name: BAYER AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEUSER, DIETER;FIERUS, MONIKA;WIEHL, WOLFGANG;REEL/FRAME:010633/0974;SIGNING DATES FROM 19990823 TO 19990825 |
    2005-07-27| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2007-05-29| CC| Certificate of correction|
    2009-01-23| FPAY| Fee payment|Year of fee payment: 4 |
    2009-11-18| AS| Assignment|Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER AKTIENGESELLSCHAFT;REEL/FRAME:023525/0710 Effective date: 20090918 |
    2013-01-16| FPAY| Fee payment|Year of fee payment: 8 |
    2016-09-15| AS| Assignment|Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:039756/0128 Effective date: 20160907 |
    2017-02-02| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    DE19715594A|DE19715594A1|1997-04-15|1997-04-15|Analgesic combination|
    DE19715594.4||1997-04-15||
    PCT/EP1998/001926|WO1998046235A1|1997-04-15|1998-04-02|Analgesic combination|
    [返回顶部]